This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...